Entering text into the input field will update the search result below

Theravance inhalable lung disease candidate shows encouraging action in early-stage study

Sep. 09, 2019 12:35 PM ETTheravance Biopharma, Inc. (TBPH) StockTBPHBy: Douglas W. House, SA News Editor
  • Initial data from a Phase 1 clinical trial evaluating single and multiple ascending doses of Theravance Biopharma's (TBPH -0.1%) inhalable JAK inhibitor TD-8236 in healthy volunteers and patients with mild asthma showed a favorable safety profile.
  • Single doses up to 4,500 mcg in healthy subjects and daily doses of up to 4,000 mcg for seven consecutive days in mild asthma sufferers were generally well-tolerated with no evidence of local irritation or bronchoconstriction. Most adverse events were mild and all were resolved by follow-up visits.
  • On a pharmacokinetic basis, plasma levels of TD-8236 were several orders of magnitude below those predicted to cause systemic pharmacological activity (therapeutic effect should be restricted to the lungs).
  • The company has initiated a Part C extension portion that will assess a range of additional biomarkers in patients with more severe asthma. A Phase 2 lung allergen challenge study will also be launched.

Recommended For You

More Trending News

About TBPH Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
TBPH--
Theravance Biopharma, Inc.